Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus

Published:2019-11-05 Issue:2 Volume:22 Page:191-202
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Zhang Hong¹^ORCID,Zhu Xiaoxue¹,Li Xiaojiao¹,Chen Hong¹,Wu Min¹,Li Cuiyun¹,Liu Jingrui¹,Liu Chengjiao¹,Zhang Yingjun²,Ding Yanhua¹

Affiliation:

1. Phase I Clinical Research CentreFirst Hospital of Jilin University Jilin China

2. State Key Laboratory of Anti‐Infective Drug Development, HEC R&D CentreSunshine Lake Pharma Co., Ltd Dongguan Guangzhou, China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13887

Reference35 articles.

1. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045

2. Prevalence of Diabetes among Men and Women in China

3. Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus;Ojha A;Clin Pharmacol,2019

4. EDITORIAL (Thematic issue: Treatment and Diagnosis of Diabetes Mellitus and Its Complication: Advanced Approaches)

5. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus;Acta Pharmaceutica Sinica B;2024-02

2. Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals;Expert Opinion on Investigational Drugs;2021-01-13

3. Simple and effective purification of a SGLT-2 inhibitor cocrystal Rongliflozin l-pyroglutamic acid: coformer-induced purification;CrystEngComm;2021

4. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus;Diabetes, Obesity and Metabolism;2020-09-02

5. A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State;Clinical Therapeutics;2020-05